Apotex Sues Merck Over Lost Sales Of Generic Fosamax
In its quarterly report filed Monday with the Securities and Exchange Commission, Merck said that the Federal Court of Canada refused in May to block the approval of generic Fosamax, known as alendronate, because Merck's patent for weekly alendronate was likely invalid.
The decision can't be appealed, and the drug was launched in Canada in June.
Apotex filed its lawsuit in the Federal...
To view the full article, register now.